AKTS
NASDAQAktis Oncology Inc.
Website
News25/Ratings9
News · 26 weeks50+500%
2025-10-262026-04-19
Mix1390d
- Analyst5(38%)
- Other2(15%)
- SEC Filings2(15%)
- Insider2(15%)
- Offering1(8%)
- Leadership1(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Gormley Glenn4 - Aktis Oncology, Inc. (0002035832) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gormley Glenn3 - Aktis Oncology, Inc. (0002035832) (Issuer)
- SECSEC Form 8-K filed by Aktis Oncology Inc.8-K - Aktis Oncology, Inc. (0002035832) (Filer)
- PRAktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of DirectorsBOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the Company's newly established Science and Technology Committee of the Board of Directors. "We are delighted to welcome Glenn to our Board as we continue to make significant progress toward upcoming clinical and corporate milestones," said Matthew Roden, PhD, President a
- SECSEC Form 10-K filed by Aktis Oncology Inc.10-K - Aktis Oncology, Inc. (0002035832) (Filer)
- PRAktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial ResultsProgressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial
- ANALYSTH.C. Wainwright initiated coverage on Aktis Oncology with a new price targetH.C. Wainwright initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $30.00
- PRAktis Oncology to Present at Upcoming March Investor ConferencesBOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference Date & Time: Tuesday, March 3, 2026, at 1:10 p.m. ETLocation: Boston, MA Leerink Partners Global Healthcare ConferenceDate & Time: Monday, March 9, 2026, at 1:40 p.m. ETLocation: Miami, FL A live w
- PRAktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein RadioconjugateU.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b trial of AKY-1189 enrolling patients with locally advanced or metastatic urothelial cancer and several other Nectin-4 expressing tumor types BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that the U.S. Food and Drug Administ
- ANALYSTAnalyst initiated coverage on Aktis Oncology with a new price targetAnalyst initiated coverage of Aktis Oncology with a rating of Overweight and set a new price target of $30.00
- ANALYSTBofA Securities initiated coverage on Aktis Oncology with a new price targetBofA Securities initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $34.00
- ANALYSTLeerink Partners initiated coverage on Aktis Oncology with a new price targetLeerink Partners initiated coverage of Aktis Oncology with a rating of Outperform and set a new price target of $31.00
- ANALYSTTD Cowen initiated coverage on Aktis OncologyTD Cowen initiated coverage of Aktis Oncology with a rating of Buy
- SECSEC Form SCHEDULE 13D filed by Aktis Oncology Inc.SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)
- SECSEC Form SCHEDULE 13D filed by Aktis Oncology Inc.SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)
- INSIDERNew insider Eli Lilly & Co claimed ownership of 6,344,114 shares (SEC Form 3)3 - Aktis Oncology, Inc. (0002035832) (Issuer)
- SECSEC Form SCHEDULE 13D filed by Aktis Oncology Inc.SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)
- INSIDERDirector Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)4 - Aktis Oncology, Inc. (0002035832) (Issuer)
- INSIDERLarge owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)4 - Aktis Oncology, Inc. (0002035832) (Issuer)
- INSIDERLarge owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)4 - Aktis Oncology, Inc. (0002035832) (Issuer)
- SECSEC Form SCHEDULE 13D filed by Aktis Oncology Inc.SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)
- PRAktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesBOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the closing of its upsized initial public offering of 17,650,000 shares of its common stock, at an initial public offering price of $18.00 per share, occurred on January 12, 2026. In addition, the underwriters exercised in full their option to purchase an additional 2,647,500 shares of Aktis' common stock, at the initial public offering price of $18.00 per share. The sale of the 2,647,500 additi
- INSIDERDirector Ecor1 Capital, Llc converted options into 2,602,247 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)4 - Aktis Oncology, Inc. (0002035832) (Issuer)
- INSIDERLarge owner Vida Ventures Ii, Llc converted options into 4,994,212 shares and bought $15,030,000 worth of shares (835,000 units at $18.00) (SEC Form 4)4 - Aktis Oncology, Inc. (0002035832) (Issuer)
- INSIDERDirector Kim Helen Susan converted options into 4,994,212 shares and bought $15,030,000 worth of shares (835,000 units at $18.00) (SEC Form 4)4 - Aktis Oncology, Inc. (0002035832) (Issuer)